Same Indication

Pembrolizumab vs Sitagliptin

Pembrolizumab vs Sitagliptin: Overview

This comparison examines the pharmacological differences between Pembrolizumab and Sitagliptin.

Mechanism of Action

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Sitagliptin: DPP-4 inhibitor increasing incretin levels.

Pharmacokinetics

Half-life: Pembrolizumab — 26 days; Sitagliptin — 12.4 hours.

Chemical Properties

Molecular Formula: Sitagliptin — C16H15F6N5O.

Molecular Weight: Sitagliptin — 407.3140 g/mol.

Type: Pembrolizumab — Antibody; Sitagliptin — Small molecule.